Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
Recruiting now · Not applicable
Conditions studied: Depression - Major Depressive Disorder, Cannabis Use Disorder, Mental Disorder
In brief
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.
Key facts
- Study ID
- NCT06878859
- Run by
- Massachusetts General Hospital
- People needed
- 80
- Starts
- 2026-02-23
- Expected to finish
- 2029-06-29
- Last updated by the study team
- 2026-06-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged ≥ 18 years
- Resides in the United States
- Able to read and understand English and willing to provide informed consent/comply with the study protocol
- Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)
- Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
- Current elevated anhedonia, as indicated by the PHQ-9
- Interest in receiving treatment for their cannabis use and depression
- Meet criteria for current MDD and CUD per the DSM-5
You may not qualify if…
- History of a psychotic disorder or bipolar disorder type I/II
- Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale
- Current psychotherapy engagement
- Changes in psychotropic medication within six weeks of the start of study
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.